Clin2
NCT07699185Likely a fitRecruiting

Immunotherapy plus chemoradiation before surgery for esophageal cancer

Esophageal Squamous Cell Carcinoma

Treatments studied

Part of Cancer, Digestive system clinical trials.

This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
336 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have a type of esophageal cancer called squamous cell carcinoma, and it has not spread to distant organs.
  • You have not had any previous treatment for this cancer, including surgery, chemotherapy, or radiation.
  • You are willing and able to have surgery to remove the cancer after the study treatment.
  • You are in good general health, with adequate organ function (like kidneys, liver, and blood counts).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06509568Recruiting· Phase 2
Chemoradiation plus immunotherapy before surgery for esophageal cancer

This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.

Hangzhou, Zhejiang
NCT07312578Enrolling by invitation· Phase 2
Targeted drugs plus chemo before surgery for esophageal cancer

This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.

Beijing, Beijing Municipality
NCT06446726Recruiting· Phase 2
Low-dose radiation, chemo, and immunotherapy before esophageal cancer surgery

This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.

Chengdu, Sichuan
NCT06178211Not yet recruiting· Phase 2
Drug plus chemo before surgery for esophageal cancer

This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.

Shanghai
NCT07403435Not yet recruiting· Phase 2
Short radiation plus immunotherapy and chemo before surgery for esophageal cancer

This study tests a new combination approach before surgery for esophageal cancer. You would receive a short course of radiation together with an immunotherapy drug called serplulimab and standard chemotherapy, to see if it helps shrink the tumor and improve outcomes.

Wuhan, Hubei
NCT07751055Recruiting· Phase 2
Chemotherapy and radiation with immunotherapy before surgery for esophageal cancer

This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.

Guangzhou, Guangdong

Hear when a new Esophageal Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.